AMRN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 500.00
- PEG ratio
- 0.81
- P/B
- 0.65
- P/S (TTM)
- 1.38
- EV/EBITDA
- -5.80
Profitability & growth
- ROE (TTM)
- -8.2%
- Operating margin
- -4.6%
- Revenue growth YoY
- -21.0%
- Dividend yield
- —
- Beta
- 0.82
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Amarin Corporation PLC
Company profileAmarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of therapies for the treatment of cardiovascular disease in the United States. The company is headquartered in Dublin, Ireland.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- ONE CENTRAL PLAZA, DUBLIN, IRELAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer